Eva Gerdts

ORCID: 0000-0003-4109-2311
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiovascular Function and Risk Factors
  • Blood Pressure and Hypertension Studies
  • Cardiac Imaging and Diagnostics
  • Cardiac Valve Diseases and Treatments
  • Cardiovascular Health and Disease Prevention
  • Cardiovascular Disease and Adiposity
  • Heart Rate Variability and Autonomic Control
  • Atrial Fibrillation Management and Outcomes
  • Hormonal Regulation and Hypertension
  • Coronary Interventions and Diagnostics
  • Cardiomyopathy and Myosin Studies
  • Cardiac electrophysiology and arrhythmias
  • Sodium Intake and Health
  • Cardiac, Anesthesia and Surgical Outcomes
  • Cerebrovascular and Carotid Artery Diseases
  • Cardiovascular and exercise physiology
  • Cardiovascular and Diving-Related Complications
  • Lipoproteins and Cardiovascular Health
  • Cardiac Health and Mental Health
  • Cardiac Arrhythmias and Treatments
  • Aortic Disease and Treatment Approaches
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Cardiovascular Effects of Exercise
  • Rheumatoid Arthritis Research and Therapies
  • Infective Endocarditis Diagnosis and Management

Haukeland University Hospital
2016-2025

University of Bergen
2016-2025

Senter for Krisepsykologi
2021

Federico II University Hospital
2008-2019

Hypertension Institute
2018

Fundación Juan March
2016

ING Direct
2016

Creative Commons
2016

Umeå University
2001-2015

Skellefteå Hospital
2001-2015

Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but lipid-lowering studies have had conflicting results.We conducted randomized, double-blind trial involving 1873 patients with mild-to-moderate, asymptomatic stenosis. The received either 40 mg simvastatin plus 10 ezetimibe or placebo daily. primary outcome was composite major cardiovascular events, including death from causes, aortic-valve replacement, nonfatal myocardial infarction, hospitalization...

10.1056/nejmoa0804602 article EN New England Journal of Medicine 2008-09-03

Background— An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test ability losartan reduce left ventricular (LV) mass more than atenolol. Methods and Results— A total 960 patients with essential hypertension LV hypertrophy (LVH) on screening ECG were enrolled at centers 7 countries studied by echocardiography baseline after 1, 2, 3, 4, 5 years’ randomized therapy. Clinical examination blinded readings...

10.1161/01.cir.0000141573.44737.5a article EN Circulation 2004-08-24
John W. McEvoy Cian P. McCarthy Rosa María Bruno Sofie Brouwers Michelle Canavan and 95 more Claudio Ceconi Ruxandra Christodorescu Stella S. Daskalopoulou Charles J. Ferro Eva Gerdts Henner Hanssen Julie Harris Lucas Lauder Richard J. McManus Gerard J. Molloy Kazem Rahimi Vera Regitz‐Zagrosek Gian Paolo Rossi Else Charlotte Sandset Bart Scheenaerts Jan A. Staessen Izabella Uchmanowicz Maurizio Volterrani Rhian M. Touyz Ana Abreu Michael Hecht Olsen Marco Ambrosetti Emmanuel Androulakis Lia E. Bang Jesper Nørgaard Bech Michael A. Borger Pierre Boutouyrie Luís Bronze Sergio Buccheri Regina Dalmau Maria Carmen De Pablo Zarzosa Christian Delles Maria Manuela Fiuza Rahima Gabulova Bjørn Olav Haugen Christian Heiß Borja Ibáñez Stefan James Vikas Kapil Meral Kayıkçıoğlu Lars Køber Konstantinos C. Koskinas Emanuela H. Locati Sharon Macdonald Anastasia S. Mihailidou Borislava Mihaylova Richard Mindham Martin Bødtker Mortensen Sándor Nardai Lis Neubeck Jens Cosedis Nielsen Peter M Nilsson Agnès Pasquet Mónica Mendes Pedro Eva Prescott Amina Rakisheva Ernst Rietzschel Bianca Rocca Xavier Rosselló Jean‐Paul Schmid Eduard Shantsila Isabella Sudano Ana Teresa Timóteo Georgios Tsivgoulis Andrea Ungar Ilonca Vaartjes Frank L.J. Visseren Heinz Voeller Christiaan Vrints Adam Witkowski Maria‐Christina Zennaro Katja Zeppenfeld Naltin Shuka Nadia Laredj Noémi Pávó Ulvi Mirzoyev Philippe van de Borne Dragan Lović Arman Postadzhiyan Jure Samardžić Petros Agathangelou J Widimský Michael Hecht Olsen Wael El-Kilany Priit Pauklin Jari A. Laukkanen Romain Boulestreau Bezhan Tsinamdzgvrishvili Ulrich Kintscher Maria Marketou Dénes Páll Þórdís Jóna Hrafnkelsdóttir Eamon Dolan Talya Wolak Grzegorz Bilo

10.1093/eurheartj/ehae178 article EN other-oa European Heart Journal 2024-08-30

Retrospective studies have suggested that patients with a low transvalvular gradient in the presence of an aortic valve area < 1.0 cm² and normal ejection fraction may represent subgroup advanced stage disease, reduced stroke volume, poor prognosis requiring early surgery. We therefore evaluated outcome low-gradient "severe" stenosis (defined as mean ≤ 40 mm Hg) prospective Simvastatin Ezetimibe Aortic Stenosis (SEAS) study.Outcome was compared moderate (aortic to 1.5 cm²; 25 Hg). The...

10.1161/circulationaha.110.983510 article EN Circulation 2011-02-15

<h3>Objectives</h3> In patients with aortic stenosis (AS) left ventricular (LV) myocardial growth may exceed individual needs to compensate LV haemodynamic load leading inappropriately high mass (iLVM), a condition at risk of adverse cardiovascular events. The prognostic impact iLVM was determined in 218 asymptomatic severe AS. <h3>Methods</h3> recognised when the measured exceeded 10% expected value predicted from height, sex and stroke work (prognostic cut-off assessed by specific ROC...

10.1136/hrt.2010.192997 article EN Heart 2010-08-18

Abstract —Left ventricular (LV) hypertrophy and concentric remodeling have been defined by using a variety of indexation methods partition values (PVs) for LV mass relative wall thickness (RWT). The effects these on the distribution geometric patterns in hypertensive subjects remain unclear. Echocardiograms were obtained 941 patients with stage I to III hypertension ECG. was calculated different body size PVs identify hypertrophy: mass/body surface area (g/m 2 ) PV men/women 116/104,...

10.1161/01.hyp.35.1.6 article EN Hypertension 2000-01-01

Left ventricular hypertrophy has been suggested to mediate the relation between hypertension and left atrial enlargement, with associated risks of fibrillation stroke. However, less is known about correlates size in hypertensive patients hypertrophy. We assessed by echocardiography 941 patients, age 55 80 (mean, 66) years, electrocardiographic at baseline Losartan Intervention For Endpoint reduction study. Enlarged diameter (women, &gt;3.8 cm; men, &gt;4.2 cm) was present 56% women 38% men (...

10.1161/hy0302.105683 article EN Hypertension 2002-03-01

The influence of left atrial size on cardiovascular events during antihypertensive treatment has not been reported previously from a long-term, prospective, randomized hypertension trial. We recorded diameter by annual echocardiography and in 881 hypertensive patients (41% women) with electrocardiographic ventricular hypertrophy aged 55 to 80 (mean: 66) years mean 4.8 losartan- or atenolol-based the Losartan Intervention for Endpoint Reduction Hypertension Study. During follow-up, total 88...

10.1161/01.hyp.0000254322.96189.85 article EN Hypertension 2006-12-19

This study sought to assess the impact of valvuloarterial impedance on left ventricular (LV) myocardial systolic function in asymptomatic aortic valve stenosis (AS). In atherosclerotic AS, LV global load consists combined valvular and arterial resistance ejection. Global significantly impacts ejection fraction (EF) symptomatic but less is known about its effect AS. Echocardiograms 1,591 patients with AS (67 ± 10 years, 51% hypertensive) at baseline SEAS (Simvastatin Ezetimibe Aortic...

10.1016/j.jcmg.2008.12.021 article EN publisher-specific-oa JACC. Cardiovascular imaging 2009-04-01

AimsLess is known about the relation between in-treatment left ventricular (LV) geometry and risk of cardiovascular events. We assessed LV geometric patterns on baseline annual echocardiograms as time-varying predictors primary composite endpoint (cardiovascular death, stroke, myocardial infarction) in 937 hypertensive patients with hypertrophy during 4.8 years losartan- or atenolol-based treatment Losartan Intervention for Endpoint reduction hypertension (LIFE) echocardiography substudy.

10.1093/ejechocard/jen155 article EN European Journal of Echocardiography 2008-05-10

<h3>Objective</h3> To assess left ventricular (LV) strain and displacement their relations to LV geometry in patients with aortic stenosis (AS). <h3>Design</h3> Cross-sectional echocardiographic study AS. Peak circumferential, radial longitudinal strain, radial, transverse were measured by 2D speckle tracking. Severity of AS was assessed from energy loss index (ELI). hypertrophy present if mass/height<sup>2.7</sup> ≥46.7/49.2 g/m<sup>2.7</sup> women/men concentric relative wall thickness...

10.1136/hrt.2009.172569 article EN cc-by-nc Heart 2009-08-25

Background— Aortic valve area index adjusted for pressure recovery (energy loss [ELI]) has been suggested as a more accurate measure of aortic stenosis (AS) severity, but its prognostic value not determined in prospective study. Methods and Results— The relation between baseline ELI rate events combined total mortality hospitalization heart failure resulting from the progression AS was assessed by multivariate Cox regression reclassification analysis 1563 patients with initial asymptomatic...

10.1161/circulationaha.112.078857 article EN Circulation 2013-01-29

Background Regression of left ventricular ( LV ) hypertrophy LVH has been a goal in clinical trials. This study tests the external validity results trials on regression using large registry from tertiary care center, to identify phenotypes less likely achieve . Methods and Results Patients Campania Salute Network, free prevalent cardiovascular disease, but with echocardiographic (defined as mass index [LVMi] &gt;47 g/m 2.7 women &gt;50 men) were included. During median follow‐up 67 months,...

10.1161/jaha.116.004152 article EN cc-by-nc-nd Journal of the American Heart Association 2017-03-01

The impact of hypertension on left ventricular structure and outcome during progression aortic valve stenosis has not been reported from a large prospective study. Data 1616 patients with asymptomatic randomized to placebo-controlled treatment combined simvastatin ezetimibe in the Simvastatin Ezetimibe Aortic Stenosis Study were used. primary study end point included cardiovascular death, events, ischemic events. Hypertension was defined as history or elevated baseline blood pressure. Left...

10.1161/hypertensionaha.112.194878 article EN Hypertension 2012-05-30

Left ventricular hypertrophy (LVH; high LV mass [LVM]) is traditionally classified as concentric or eccentric based on relative wall thickness. We evaluated the prediction of subsequent adverse events in a new 4-group LVH classification dilatation (high end-diastolic volume [EDV] index) and concentricity (mass/end-diastolic [M/EDV](2/3)) hypertensive patients.In Losartan Intervention for Endpoint Reduction (LIFE) echocardiography substudy, 939 patients with measurable LVM at baseline were...

10.1161/circimaging.113.001275 article EN Circulation Cardiovascular Imaging 2014-04-11

In general, women have lower risk for cardiovascular disease. We tested whether this sex-specific protection persists also in the presence of hypertensive left ventricular hypertrophy (LVH).12,329 and men with hypertension free from prevalent disease enrolled prospective Campania Salute Network registry were followed over a median 4.1years. Subjects grouped according to absence or LVH identified by echocardiography using validated cut-off values LV mass index (>47g/m2.7 >50g/m2.7 men). Main...

10.1016/j.ijcard.2017.12.086 article EN cc-by-nc-nd International Journal of Cardiology 2018-03-13

Abstract Background and Aims Sex-based differences in the association of long-term trends pulse pressure with future risk atrial fibrillation (AF) have been explored using data from population-based Tromsø Study 1986–2016. Methods Women (n = 8331) men 7638) aged ≥20 years who attended at least two three surveys conducted between 1986 2001 (the exposure period) were followed up for incident AF throughout 2016 follow-up period). Pulse ≥60 mmHg was considered elevated. Group-based trajectory...

10.1093/eurheartj/ehaf005 article EN cc-by-nc European Heart Journal 2025-01-17

Iodine deficiency is linked to multiple adverse health outcomes, but there scarce knowledge regarding iodine intake and development of chronic hypertension. We aimed investigate the prospective association between habitual dietary pharmacologically treated hypertension in mothers up 10 years after delivery. The present study based on data from an ongoing pregnancy cohort includes 58,629 women without thyroid dysfunction at baseline. outcome was new-onset defined according antihypertensive...

10.1016/j.clnu.2025.01.001 article EN cc-by Clinical Nutrition 2025-01-07

Atrial fibrillation (AF) and heart failure (HF) often coexist impact morbidity mortality. There is limited knowledge on the association of AF subtypes with HF according to sex. The purpose this study was explore sex-specific associations between subsequent HF, identifying risk factors in participants AF, exploring combined 14,790 women 13,181 men from Tromsø Study were enrolled 1994 2008 followed for incident through 2016. Cox regression conducted provide HRs 95% CIs. Those had higher both...

10.1016/j.jacadv.2024.101556 article EN cc-by JACC Advances 2025-01-10
Coming Soon ...